Univest
Univest
  • Markets

Nifty Pharma Prediction for Monday, 16 November 2026 (Including F&O)

  • November 13, 2026
  • Posted by: Kunal Singla
  • Category: Uncategorized
No Comments
Nifty Pharma Prediction for Monday, 16 November 2026 (Including F&O)

Nifty Pharma fell 0.49% to 28,535.75. Nifty 50 fell 0.61% to 25,144.30 on Friday. India VIX fell 5.05% to 15.78. Next regular session is Monday, 16 November.

Quick Answer

The nifty pharma prediction for Monday is mildly cautious for Monday, 16 November 2026. Nifty Pharma fell 0.49 percent to 28,535.75 on Friday after opening at 28,598.60 and trading between 28,452.40 and 28,902.45. The high of 28,902.45 rose above the previous close of 28,675.75, but the index could not hold there. It fell less than the Nifty 50’s 0.61 percent decline, so it held up better than the market.

This nifty pharma prediction for Monday follows a Friday, 13 November 2026 session in which Nifty Pharma fell 0.49 percent to 28,535.75, closing about 83 points above its low of 28,452.40 after a lower open at 28,598.60.

Ankit Jaiswal, Senior Research Analyst at Univest, and Kunal Singla, Associate Director at Univest, are tracking sector-specific triggers and F&O positioning ahead of Monday’s session, the next regular trading day after Friday’s close.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Friday Told Us
  • Nifty Pharma Prediction for Monday: Key Levels
  • Key Drivers for Monday
  • Stocks and Triggers to Watch in the Nifty Pharma Space
  • How Friday’s Broader Session Unfolded
  • Analyst View for Monday
  • Why This Is Written for Monday
  • Risks to This Prediction
  • Conclusion
  • Frequently Asked Questions
    • What is the nifty pharma prediction for Monday?
    • Why is this a prediction for Monday, 16 November 2026?
    • Why did Nifty Pharma fell on Friday?
    • What levels matter for Nifty Pharma on Monday?
    • Is this a buy or sell call?

What Friday Told Us

  • Nifty Pharma fell 0.49 percent to 28,535.75, with a high of 28,902.45 and a low of 28,452.40.
  • Nifty 50 fell 0.61 percent to 25,144.30.
  • India VIX fell 5.05 percent to 15.78.
  • Most active among the stocks Univest tracked: Zee Entertainment (about 47.5 million shares), HDFC Bank (about 23.4 million) and Reliance Industries (about 13.8 million).

Nifty Pharma Prediction for Monday: Key Levels

Nifty Pharma traded between 28,452.40 and 28,902.45 on Friday, against a previous close of 28,675.75, and settled at 28,535.75. On the downside, 28,452.40 is the first reference level to watch if the day’s move is tested. On the upside, 28,598.60, 28,675.75 and 28,902.45 mark the nearest resistance. Univest’s analysts treat these as reference points drawn from Friday’s trading range, not as targets.

Trend Support Resistance
Negative 28,452.40 28,598.60, 28,675.75, 28,902.45

The index level is the headline number for this note, and the change is measured against Thursday’s close.

For traders, the nifty pharma prediction for Monday is a framework for planning risk, with position size and stop levels left to the individual.

Key Drivers for Monday

  • Nifty Pharma fell 0.49 percent, with a high of 28,902.45 and a low of 28,452.40.
  • Nifty Pharma opened at 28,598.60, below the previous close of 28,675.75, and ended 62.85 below the open.
  • Pharma fell 0.49 percent, a second straight fall after 0.35 percent on Thursday.

Ankit Jaiswal and Kunal Singla suggest revisiting this nifty pharma prediction for Monday after the first thirty minutes of Monday’s trade.

Anyone following the nifty pharma prediction for Monday should keep the opening range in view before reading too much into early moves.

Nothing in this nifty pharma prediction for Monday is a promise of returns, and every level quoted can fail.

Stocks and Triggers to Watch in the Nifty Pharma Space

Nifty Pharma fell 0.49 percent, less than the Nifty 50’s 0.61 percent. Traders usually follow US generics pricing, regulatory news and currency moves for the group, and the trigger for Friday’s fall was not independently confirmed.

In the F&O segment, the Nifty options data Univest checked shows the nearest expiry on 17 November 2026. Call open interest was highest at the 25,500 strike and put open interest at the 25,000 strike, with a put-call ratio of approximately 0.83, which means call open interest is larger than put open interest. India VIX fell 5.05 percent to 15.78. Univest’s analysts treat these strikes as reference points for the broader market, not as predictions for Nifty Pharma.

In short, the nifty pharma prediction for Monday rests on Friday’s verified close and the overnight risks listed below.

These are educational views, not buy calls, and each should be checked against your own risk plan before acting.

How Friday’s Broader Session Unfolded

The Nifty 50 closed at 25,144.30 on Friday, down 0.61 percent from Thursday’s close of 25,299.35. It opened at 25,209.85, touched a high of 25,246.35, fell to 25,054.40 and finished about 90 points above the low. The Sensex closed at 81,592.45, down 0.39 percent, while the Bank Nifty closed at 61,034.10, down 0.79 percent, after opening at its high of 61,300.55. Nifty Next 50 fell 0.83 percent and the Nifty 500 fell 0.55 percent, while Nifty Midcap 50 was almost flat, down 0.04 percent, so mid-caps held up better than the large-cap benchmark. Nifty Auto fell 1.07 percent and Nifty Metal fell 0.98 percent, while Nifty FMCG was almost flat, down 0.01 percent, and Nifty PSU Bank fell 0.51 percent. India VIX, the market’s fear gauge, fell 5.05 percent to 15.78 from 16.62, after trading between 15.30 and 16.88 during the day. In the options market, the Nifty put-call ratio was approximately 0.83, with call open interest highest at the 25,500 strike and put open interest highest at 25,000, for the 17 November expiry. The trigger for Friday’s moves was not independently confirmed.

Placed against that backdrop, the nifty pharma prediction for Monday reads Friday’s move in the context of a broader market that closed lower.

Analyst View for Monday

Kunal Singla suggests that Nifty Pharma needs a recovery toward 28,675.75, the previous close, to improve the tone, with 28,452.40 the first support.

Ankit Jaiswal flags that the index rose to 28,902.45 early and gave it all back, so that high is the level to clear, while 28,452.40 is the low to hold

Both analysts stress that the nifty pharma prediction for Monday is a view built on levels and data, not a forecast of returns.

A fair reading of this nifty pharma prediction for Monday is that Friday’s data sets the context, while Monday’s first hour decides how much of it carries forward.

Why This Is Written for Monday

This nifty pharma prediction for Monday is written on Friday, 13 November 2026, after the close, using today’s closing data, for the next regular trading session on Monday, 16 November 2026. NSE and BSE traded as normal today, Saturday and Sunday are non-trading days, and Monday is a regular session with no exchange holiday.

Because the equity market is shut for the day, the nifty pharma prediction for Monday relies on Friday’s close rather than any live price.

Overseas markets and currency moves over the weekend can open Monday with a gap in either direction. Treat this as a briefing to prepare for the session, not a live call that updates through the day.

Track the Nifty Pharma Space on Univest Screeners

Risks to This Prediction

  • A move back above the previous close of 28,675.75 would soften the cautious view, while a break below the low of 28,452.40 would deepen the weakness.
  • US pricing commentary on generics can move the group quickly.
  • Rotation within sectors can shift quickly after two weak sessions.

Readers comparing views should note that this nifty pharma prediction for Monday draws only on Friday’s closing numbers and the factors listed here.

As with any nifty pharma prediction for Monday, the opening minutes of Monday’s trade will confirm or challenge the levels discussed here.

Download the Univest iOS App or Univest Android App to get daily market recommendations and insightful research pieces.

Conclusion

The nifty pharma prediction for Monday leans mildly cautious into 16 November 2026, with US generics pricing and sector rotation as the key variables to track. Ankit Jaiswal and Kunal Singla will revisit this view once Monday’s opening trade confirms direction.

Disclaimer: Investments in securities are subject to market risk. Read all related documents carefully before investing. The information provided here is for educational purposes only and does not constitute investment advice. Univest is a SEBI-registered investment adviser (Registration No. INH000013776). Past performance is not indicative of future returns.

Frequently Asked Questions

What is the nifty pharma prediction for Monday?

Ans. It is mildly cautious for 16 November 2026, after Nifty Pharma fell 0.49 percent to 28,535.75 on Friday.

Why is this a prediction for Monday, 16 November 2026?

Ans. Because this note is published on Friday, 13 November 2026, after the close, and the next regular trading session is Monday, 16 November 2026. Saturday and Sunday are non-trading days, and there is no exchange holiday on Monday.

Why did Nifty Pharma fell on Friday?

Ans. Nifty Pharma fell 0.49 percent to 28,535.75. The specific trigger was not independently confirmed.

What levels matter for Nifty Pharma on Monday?

Ans. Support sits near 28,452.40. Resistance sits near 28,598.60, 28,675.75 and 28,902.45.

Is this a buy or sell call?

Ans. No. This is an educational outlook from Univest’s research team, not a buy or sell call. Traders should check any view against their own risk plan before acting.



Nifty Pharma
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply